Jeffrey Robert Ajer, Director at NEKTAR THERAPEUTICS (NKTR), sold 2,250 shares at $19.74 ($44K) on 2020-09-21, disclosed to the SEC on 2020-09-21.
Scheduled sale ($44k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| NKTR | SELL | 2023-09-20 | $3K | — | Filing → |
| BMRN | SELL | 2023-08-17 | $450K | — | Filing → |
| BMRN | SELL | 2023-01-27 | $11.3M | — | Filing → |